Authors
Latest:
Fellows Can Join the Fight Against Cancer Misinformation OnlineMany cancer organizations across the United States and internationally acknowledge a need for in-novative uses of social technology to improve cancer-related support and information provision.
Latest:
Washington on Efforts to Address Disparities in Cancer CareChasity Washington, MPH, CHES, discusses strategies for addressing disparities in cancer care.
Latest:
Dr Aranha on Data Informing HIPEC Use in Peritoneal Carcinomatosis of GI MalignanciesOlivia Aranha, MD, PhD, discusses data supporting the use of HIPEC for patients with peritoneal carcinomatosis in gastrointestinal malignancies.
Latest:
Transposon-Based BAFF CAR T Cells Show Early Efficacy, Safety in R/R Non-Hodgkin LymphomaTransposon-engineered BAFF ligand–based CAR T cells induced responses with a tolerable safety profile among 3 patients with relapsed/refractory B-cell NHL.
Latest:
Dr. Mogal on the Role of Cytoreductive Surgery in Colorectal Peritoneal CarcinomatosisHarveshp D. Mogal, MD, MS, FACS, DABS, FSSO, discusses the role of cytoreductive surgery in colorectal peritoneal carcinomatosis.
Latest:
Advice for New Nurse Practitioners Working With Patients With Endometrial CancerClosing their discussion, the panel shares advice for new nurse practitioners caring for patients who have endometrial cancer.
Latest:
Dr. Alkharabsheh on Remaining Challenges in High-Risk CLLOmar Alkharabsheh, MD, discusses remaining challenges in high-risk chronic lymphocytic leukemia.
Latest:
Using Multidisciplinary Care to Optimize Outcomes in GVHDSharing closing thoughts on acute and chronic GVHD management, expert panelists first consider the value of multidisciplinary care.
Latest:
Zanubrutinib plus Obinutuzumab versus Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Analysis of the ROSEWOOD StudyDr. Christopher Flowers showcases a comprehensive and updated analysis of the ROSEWOOD study, evaluating the efficacy and safety of combining zanubrutinib with obinutuzumab versus obinutuzumab monotherapy.
Latest:
Practice Pearls for Toxicity Management With ADC Therapy in Breast and Gastric CancerShared practical advice on the management of toxicities associated with antibody drug conjugate therapy in both the breast cancer and GI cancer settings.
Latest:
Camidge and Rabinowitz Reflect on Finding Strength and Inspiration on Both Sides of a Cancer DiagnosisDrs Camidge and Rabinowitz discuss the balance between professional and personal life that Rabinowitz navigated when he was diagnosed with lung cancer.
Latest:
Multidisciplinary Strategies in RCC Management: Future Directions in CareClosing out their discussion on renal cell carcinoma, key opinion leaders highlight the value of multidisciplinary care and look toward future evolutions in the treatment paradigm.
Latest:
Putting Culturally Competent Care into PracticeJoseph Mikhael, MD, and Craig Cole, MD, close the program by sharing examples of times culturally competent care was paramount to the treatment of their patients.
Latest:
Trainees Deserve Better FeedbackFeedback plays a key role in medical edu-cation and faculty development as it allows everyone to evaluate their performance and improve their intrapersonal skills.
Latest:
Novel Frontline Combinations Influence Later-Line Treatment Strategies in SCLCWhile progress in outcomes has been greater in non–small cell lung cancer, recent advances, including molecularly targeted therapies against EGFR and ALK, checkpoint inhibitors that boost immune response, improved staging, and video-assisted surgery have all contributed to progress in treatment of all types of lung cancer, including in SCLC.
Latest:
Unmet Needs and Future of Lower-Risk MDSThe panel concludes their discussion with a look toward the future of lower-risk myelodysplastic syndrome treatment and the unmet needs that should be addressed.
Latest:
Polatuzumab Vedotin Substitution in R-mini-CHOP Does Not Worsen High-Grade Toxicities in DLBCLUsing polatuzumab vedotin instead of vincristine in a reduced-dose regimen of rituximab, cyclophosphamide, doxorubicin, and prednisone was not found to increase grade 3/4 hematologic toxicities, infection risk, or neuropathy in elderly patients with untreated diffuse large B-cell lymphoma.
Latest:
Dr Chaudhary on the Utilization of Trastuzumab Deruxtecan in Metastatic HER2+ Breast CancerLubna Chaudhary, MD, MS, discusses the ongoing investigation and utilization of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and compared this agent’s efficacy with that of trastuzumab emtansine.
Latest:
Dr Narayan on the Utility of Nadofaragene Firadenovec in NMIBC and BeyondVikram M. Narayan, MD, discusses the utility of nadofaragene firadenovec in patients with non–muscle-invasive bladder cancer and beyond.
Latest:
Dr Liu on the Activity of Trastuzumab Deruxtecan in HER2-Mutated NSCLCStephen V. Liu, MD, discusses the activity of trastuzumab deruxtecan in patients with HER2-mutated non–small cell lung cancer.
Latest:
Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and TreatmentLearn more about the epidemiology, diagnosis, and treatment of advanced systemic mastocytosis in this summary from an expert multidisciplinary case-based discussion.
Latest:
Dr Masters on the 2024 ACRO SummitAdrianna Masters, MD, PhD, discusses pivotal events from the 2024 ACRO Summit, emphasizing the importance of mentorship in radiation oncology.
Latest:
Dr Alvarado on Selecting Breast Conservation Surgery vs Mastectomy After Neoadjuvant TherapyMichael D. Alvarado, MD, discusses the decision to undergo breast conservation surgery vs mastectomy following neoadjuvant breast cancer therapy.
Latest:
Dr. Fountzilas on Molecular Characterization in mCRCChristos Fountzilas, MD, FACP, discusses findings from a study of molecular characterization in patients with colorectal cancer treated with cetuximab, an EGFR inhibitor, and pembrolizumab, a PD-1 inhibitor.
Latest:
Experts Discuss the Risk of Skin Toxicities Associated With EGFR TKIsJeanne G. Vaughn, NP, Kristina Lo, PharmD, BCOP, Jonathan Riess, MD, MS, and Ticiana Leal, MD, discuss the impact of skin toxicities when utilizing EGFR TKIs.
Latest:
Dr Richardson on Escalating Rates of Uterine Cancer Among Asian AmericansMichael Richardson, MD, discusses escalating uterine cancer rates among Asian Americans.
Latest:
Dr Liu on the Frequency of Activating ERBB2 and ERBB3 Alterations in NSCLCDazhi Liu, PharmD, MS, BCOP, discusses findings from a real-world analysis of the frequency of ERBB2 and ERBB3 alterations in patients with non–small cell lung cancer and the efficacy of liquid vs tissue biopsies for detecting these alterations.
Latest:
Vorasidenib Shows Consistent Efficacy With Manageable Safety in IDH1/2-Mutant Diffuse GliomaUpdated INDIGO data reveal that vorasidenib continues to showcase improved efficacy over placebo in patients with IDH1/2-mutated diffuse glioma.
